Compare SAMG & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SAMG | ELDN |
|---|---|---|
| Founded | 2002 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.5M | 208.6M |
| IPO Year | 2012 | 2014 |
| Metric | SAMG | ELDN |
|---|---|---|
| Price | $14.75 | $2.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 18.5K | ★ 900.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 5.64% | N/A |
| EPS Growth | N/A | ★ 54.27 |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $91,358,000.00 | N/A |
| Revenue This Year | $3.37 | N/A |
| Revenue Next Year | $10.62 | N/A |
| P/E Ratio | $27.09 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.23 | $1.35 |
| 52 Week High | $17.01 | $4.60 |
| Indicator | SAMG | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 39.74 | 59.49 |
| Support Level | $14.47 | $2.48 |
| Resistance Level | $15.50 | $2.77 |
| Average True Range (ATR) | 0.42 | 0.21 |
| MACD | -0.07 | 0.03 |
| Stochastic Oscillator | 31.61 | 56.22 |
Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income and cash as well as non-traditional investment strategies including hedge funds, private equity funds, real estate and commodities. It also provides clients with family office services and related administrative services, which include financial planning, tax planning and preparation, partnership accounting and fund administration, and consolidated wealth reporting. The company derives revenues principally from assets under management.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.